Oxime functionalized Chalcones: Unveiling a new class of Chalcones with potent Antiplasmodial activity against blood-stages of Plasmodium falciparum in culture
{"title":"Oxime functionalized Chalcones: Unveiling a new class of Chalcones with potent Antiplasmodial activity against blood-stages of Plasmodium falciparum in culture","authors":"Reeta Chaudhary , Ayushee , Vinoth Rajendran , T.M. Rangarajan","doi":"10.1016/j.bmcl.2025.130143","DOIUrl":null,"url":null,"abstract":"<div><div>The <em>Plasmodium falciparum</em> parasite, which is responsible for malaria, has developed resistance to several first-line antimalarial drugs. To address this issue, researchers have been developing novel hybrid molecules that can inhibit parasite growth. In this study, a total of 38 chalcone oxime ethers, consisting of four different types, were evaluated for <em>in vitro</em> blood-stage antiplasmodial activity against <em>P. falciparum</em> (3D7) using SYBR green I assay. The four classes of oxime ethers showed promising to moderate antiplasmodial activity. At least one molecule from each class was potent, with the IC<sub>50</sub> values of less than 5 μg/mL. Among the four classes, chalcone-chalconeoxime ethers (CCOE) were the most effective, with the IC<sub>50</sub> values of 1.55 μg/mL and 1.4 μg/mL for <strong>CCOE-2</strong> and <strong>CCOE-5</strong>, respectively. The most potent molecules, <strong>CKOE-13</strong>, <strong>COAE-2</strong>, <strong>CCOE-2</strong>, and <strong>CCOE-5</strong>, were tested against the chloroquine-resistant strain <em>P. falciparum</em> (INDO) exhibited IC<sub>50</sub> values of less than 5 μg/mL. Notably, the most potent molecules did not induce hemolysis at concentrations up to 50 μg/mL. These findings highlight a new class of chalconeoxime ethers as potent antiplasmodial agents, warranting further exploration of their biological activities.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"121 ","pages":"Article 130143"},"PeriodicalIF":2.5000,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioorganic & Medicinal Chemistry Letters","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0960894X25000526","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
The Plasmodium falciparum parasite, which is responsible for malaria, has developed resistance to several first-line antimalarial drugs. To address this issue, researchers have been developing novel hybrid molecules that can inhibit parasite growth. In this study, a total of 38 chalcone oxime ethers, consisting of four different types, were evaluated for in vitro blood-stage antiplasmodial activity against P. falciparum (3D7) using SYBR green I assay. The four classes of oxime ethers showed promising to moderate antiplasmodial activity. At least one molecule from each class was potent, with the IC50 values of less than 5 μg/mL. Among the four classes, chalcone-chalconeoxime ethers (CCOE) were the most effective, with the IC50 values of 1.55 μg/mL and 1.4 μg/mL for CCOE-2 and CCOE-5, respectively. The most potent molecules, CKOE-13, COAE-2, CCOE-2, and CCOE-5, were tested against the chloroquine-resistant strain P. falciparum (INDO) exhibited IC50 values of less than 5 μg/mL. Notably, the most potent molecules did not induce hemolysis at concentrations up to 50 μg/mL. These findings highlight a new class of chalconeoxime ethers as potent antiplasmodial agents, warranting further exploration of their biological activities.
期刊介绍:
Bioorganic & Medicinal Chemistry Letters presents preliminary experimental or theoretical research results of outstanding significance and timeliness on all aspects of science at the interface of chemistry and biology and on major advances in drug design and development. The journal publishes articles in the form of communications reporting experimental or theoretical results of special interest, and strives to provide maximum dissemination to a large, international audience.